Paul Stoffels, Galapagos CEO (Andrew Harnik/AP Images)
February 24, 2023 10:02 AM EST
R&D

Gala­pa­gos goes 0-for-3 on in­flam­ma­tion pro­gram as it cuts an ear­ly-stage can­di­date

Lei Lei Wu

News Reporter

Gala­pa­gos has cut an­ti-in­flam­ma­to­ry drug can­di­date GLPG4399 fol­low­ing the com­ple­tion of an ear­ly-stage healthy vol­un­teer tri­al, ac­cord­ing to its 2022 an­nu­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times